FDA Grants Breakthrough Status to Promising Head and Neck Cancer Treatment

Bicara Therapeutics' ficerafusp alfa receives FDA Breakthrough Therapy Designation for HPV-negative head and neck cancer, showing impressive response rates and survival benefits.